# Linker chemistry: the conjugation science inside every ADC

Cleavable versus non-cleavable linkers, why site-specific conjugation tightened the drug-to-antibody ratio, and how high-potency containment defines the industrial economics of ADCs.

An antibody-drug conjugate is a delivery contract written in chemistry: the linker specifies where the payload rides, when it detaches, and what the manufacturing plant must contain.

Source: https://en.bioecon.ru/docs/health-biomedicine/therapeutics-platforms/adc-linker-chemistry/
Updated: 2026-09-18



Every antibody-drug conjugate is a bargain among three imperfect components. The antibody is a guided vehicle that is not toxic. The payload is lethal but blind. The linker is the contract between them, and its chemistry decides whether the bargain holds. Early ADCs failed on this clause: hydrazide and disulfide linkers of the first generation released payload in plasma fast enough that the drugs behaved like weakly directed chemotherapy. The modern toolkit answers with chemistry tuned to biology — dipeptide motifs that only lysosomal cathepsins cut efficiently, disulfides shielded by methyl groups until reduction inside the cell, and non-cleavable thioethers that never release the payload whole, relying on the target cell to digest the antibody down to the attached amino acid.

The second idea is distribution, not just stability. Classical conjugation couples payload to lysines statistically, producing a mixture of species carrying anywhere from zero to eight drugs per antibody — a distribution that is purified, characterized, and dosed as an average. Site-specific methods replace the distribution with a molecule: engineered cysteines, glycan remodeling or enzymatic tags put payloads at defined positions, so every molecule in the vial carries the same drug-to-antibody ratio. The therapeutic consequence is a narrower gap between effective and toxic exposure; the manufacturing consequence is a new set of analytical obligations, because a homogeneous product must prove homogeneity batch after batch.

The third idea is industrial: payload chemistry does not scale like antibody chemistry. Cytotoxins are handled at occupational exposure limits measured in nanograms per cubic meter, so the plant around an ADC campaign is isolators, closed transfers and cryogenic reactions — a chemical plant bolted onto a biologics suite. The economics follow the containment: payload-linker GMP, conjugation, and fill-finish integrated on one site exist because every transfer between sites is a contamination and exposure risk. This is why the conjugate business consolidated into integrated organizations that carry a molecule from antibody to vial under one quality system.

The integrated model shows in today's capacity figures. The global ADC CRDMO leader conjugates from 5 to 2,000 litres with antibody drug substance made in the same building, fills up to 15 million doses a year, and is adding a Singapore site planned to be operational in 2026 — dual sourcing is what multi-region filings demand. Behind an approved disitamab vedotin, a Chinese originator plans to grow from 36,000 to 80,000 litres. Capacity of this kind is dedicated, containment-bound, and built ahead of filed indications — which is why it, not the antibody, sets the pace of the industry.

What the chemistry cannot yet do is worth stating plainly. Linkers still release meaningful payload before reaching the tumor, and the release triggers — cathepsin abundance, acidity, glutathione — are statistical properties of tumors, not switches. Resistance arrives by changing exactly those properties, or by degrading the antigen the antibody targets. The field's response has been to make the contract more specific rather than more powerful: better positions, cleaner release, payloads whose bystander effect stays local. The unmet need is not a stronger toxin but a linker whose behavior in the patient matches its behavior in the release assay — a stability problem that remains, at bottom, a chemistry problem.